Experimental and Molecular Medicine

Experimental & Molecular Medicine is a monthly peer-reviewed open-access journal published by Springer Nature on behalf of the Korean Society for Biochemistry and Molecular Biology, first founded in 1964 and relaunched under its current title in 1996, covering molecular and cellular studies of human physiology and disease, with a 2025 Journal Impact Factor of 17.5《实验与分子医学》是由施普林格·自然（Springer Nature）代表（Korean Society for Biochemistry and Molecular Biology）出版的月刊同行评审开放获取期刊，1964 年创办并于 1996 年以现名重新创办，刊载人类生理与疾病的分子与细胞研究，2025 年影响因子为 17.5。

Scope

• It is devoted to publishing the latest and most important advances in genetic, molecular and cellular studies of human physiology and diseases该刊致力于发表人类生理与疾病在遗传、分子与细胞研究方面的最新且最重要的进展。
• It aims to communicate clinical benefits for human health arising from experimental and translational research performed using molecular tools该刊旨在传播借助分子工具开展的实验与转化研究所带来的人类健康临床获益。
• Covered areas include cancer biology and immunology涵盖领域包括癌症生物学与免疫学。
• They also include neuroscience and cardiovascular diseases还包括神经科学与心血管疾病。
• They also include genetics and genomics, gene therapy, and stem cells and regenerative medicine还包括遗传学与基因组学、基因治疗，以及干细胞与再生医学。
• It is a fully peer-reviewed, open access international journal该刊是经完整同行评审的开放获取国际期刊。
• It publishes original research articles and review articles该刊刊载原创研究论文与综述文章。

History

• It was founded in 1964 as The Korean Journal of Biochemistry, Korea's first biomedical science journal and the first Korean scientific journal to publish only papers in English该刊于 1964 年创刊，初名（The Korean Journal of Biochemistry），是韩国首份生物医学期刊，也是韩国首份仅发表英文论文的科学期刊。
• It was renamed Journal of Biochemistry and Molecular Biology and then relaunched as Experimental & Molecular Medicine in 1996 with a new scope focused on molecular medicine该刊先更名为（Journal of Biochemistry and Molecular Biology），随后于 1996 年以《实验与分子医学》重新创办，新定位聚焦分子医学。
• It has been published in cooperation with the Nature Publishing Group, now part of Springer Nature, since 2013该刊自 2013 年起与（Nature Publishing Group）合作出版，该集团现属（Springer Nature）。^[1]
• It appeared in print and online until 2012 and has been published online only since 2013该刊至 2012 年在印刷版与网络版同时发行，自 2013 年起仅在线出版。
• It was accepted for coverage in the Institute for Scientific Information Web of Science in 2002该刊于 2002 年被（Institute for Scientific Information）的（Web of Science）收录。
• Its Journal Impact Factor was 8.718 in 2021, 12.153 in 2022 and 12.9 in 2024, reaching 17.5 in 2025其影响因子 2021 年为 8.718、2022 年为 12.153、2024 年为 12.9，2025 年达到 17.5。
• In the 2025 Journal Citation Reports it holds Q1 placings in medicine, research and experimental, and in biochemistry and molecular biology在 2025 年期刊引证报告中，该刊于医学研究与实验、以及生物化学与分子生物学类别均位列 Q1。

Editors

• Its Editor-in-Chief is Dae-Myung Jue, a professor in the Department of Biochemistry at the Catholic University of Korea in Seoul现任主编为 Dae-Myung Jue，是（Catholic University of Korea）生物化学系教授，居于首尔。
• Jue has taken part in the journal's editorial work since 1995 and was president of the Korean Society of Medical Biochemistry and Molecular Biology in 2008Dae-Myung Jue 自 1995 年起参与该刊编辑工作，并于 2008 年担任（Korean Society of Medical Biochemistry and Molecular Biology）会长。
• Its Associate Editors include Sung-Yup Cho of the Seoul National University College of Medicine其副编辑包括（Seoul National University）医学院的 Sung-Yup Cho。
• Associate Editors also include Dong Ho Choi, Je-Min Choi and Mi-Na Kweon副编辑还包括 Dong Ho Choi、Je-Min Choi 与 Mi-Na Kweon。
• It is edited on behalf of the Korean Society for Biochemistry and Molecular Biology该刊代表（Korean Society for Biochemistry and Molecular Biology）编辑出版。
• Manuscripts are assessed by peer reviewers and selected for the journal's scope稿件由同行评审人评估，并按其是否符合该刊定位进行遴选。